These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11198266)

  • 1. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
    Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E
    Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
    Schneider J; Velcovsky HG; Morr H; Katz N; Neu K; Eigenbrodt E
    Anticancer Res; 2000; 20(6D):5053-8. PubMed ID: 11326667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
    Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring.
    Schneider J; Neu K; Grimm H; Velcovsky HG; Weisse G; Eigenbrodt E
    Anticancer Res; 2002; 22(1A):311-8. PubMed ID: 12017309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B; Bagga R; Patel FD
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F; Fischer G; Eigenbrodt E
    Anticancer Res; 1999; 19(4A):2753-7. PubMed ID: 10470235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J; Fuchs H; Niemann VT; Hoffmeister B
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
    Zhang S; Ma Y; Yang X
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
    Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
    Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
    Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
    Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
    Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
    Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
    Oremek GM; Sapoutzis N; Kramer W; Bickeböller R; Jonas D
    Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM; Gerstmeier F; Sauer-Eppel H; Sapoutzis N; Wechsel HW
    Anticancer Res; 2003; 23(2A):1127-30. PubMed ID: 12820359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW; Petri E; Bichler KH; Feil G
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma.
    Kong F; Jirtle RL; Huang DH; Clough RW; Anscher MS
    Cancer; 1999 Nov; 86(9):1712-9. PubMed ID: 10547543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.